I wonder why CureVac N.V.’s (CVAC) stock fell in the pre-market session today?

0
1685

Despite CureVac N.V.’s (CVAC) own lack of news, several stocks in the sector have been impacted due to a piece of larger market news, As the CureVac N.V, (CVAC) stock plunged -11.33% to $103.05 in the premarketing session today.

However, the company announced on December 14, 2020, that a pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, has enrolled its first participant against COVID-19. CVAC is developing transformative medicines based on messenger ribonucleic acid (mRNA).


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Researchers at the randomized, observing blind, placebo-controlled Phase 2b/3 trial HERALD are planning to assess the safety and efficacy of CVnCoV at a dose of 12 g across Europe and Latin America.

There are also two primary efficacy objectives in addition to the primary safety objective: demonstrating the efficacy of CVnCoV in preventing COVID-19 cases of any severity in participants who have never been infected with the SARS-CoV-2.

There are also two primary efficacy objectives in addition to the primary safety objective: demonstrating the efficacy of CVnCoV in preventing COVID-19 cases of any severity in participants who have never been infected with the SARS-CoV-2.

Researchers will assess the effect of CVnCoV by analyzing symptomatic COVID-19 disease in a certain number of participants based on an event-driven analysis. As part of the participants’ continuous safety monitoring in the trials, the data will be reviewed regularly by an independent Data Safety Monitoring Board.

The extension study will collect additional data to assess and evaluate the durability of vaccine efficacy, the persistence of antibodies to SARS-CoV-2, and the occurrence of COVID-19 cases after completion of the trial.

LEAVE A REPLY

Please enter your comment!
Please enter your name here